Juyuan Bio Completes Over RMB 100 Million Financing to Accelerate Sustainable Development in Synthetic Biology
Recently,Jiangsu Jland Biotech Co., Ltd. Officially Completes Over RMB 100 Million in Financing, with Joint Investment from SDIC Merchants and YUEXIU Industrial FundThe financing will enable Jiangsu Jland Biotech Co., Ltd. to strengthen its strategic layout in the field of biosynthesis, comprehensively enhancing its overall competitiveness as a globally leading “intelligent manufacturing platform” for functional proteins in synthetic biology.
Recombinant Collagen: Charting a New Future for the Biomanufacturing Industry:
China’s biomanufacturing sector is ushering in unprecedented development opportunities. In 2025, the nation will prioritize biomanufacturing as a key future industry, aiming to drive the transformation and upgrading of traditional industries, bolster China’s leading position in critical areas such as technological innovation, industrial upgrading, healthcare, and the green economy, and ignite new engines of economic growth.
As a national high-tech enterprise focused on the R&D and production of recombinant collagen and multi-type functional proteins driven by synthetic biology, Juyuan Biotech has been deeply engaged in recombinant collagen for over two decades. The company has established a full-industry-chain platform encompassing gene design, strain construction, industrialization design, ton-scale capacity scale-up, downstream application R&D, and safety and efficacy testing of downstream products. It is the only enterprise in the industry to provide end-to-end services from sequence design to product customization.
Juyuan Biotech’s development strategy aligns closely with China’s national strategies in the field of biomanufacturing. The company is driving innovation in sustainable biomaterials across high-end dressings, artificial skin, and tissue engineering, while making significant progress in breakthroughs in key technologies, integration of the industrial chain, and formulation of national and industry standards. These efforts directly support the national goals of building a “manufacturing powerhouse,” advancing “Healthy China,” and achieving “dual carbon” targets, while keeping pace with the accelerating global evolution of biotechnology.
Jiangsu Jland Biotech Co., Ltd. is one of the earliest enterprises in China to achieve ton-scale industrial production of recombinant collagen using the Pichia pastoris expression system. Leveraging industry-leading biotechnologies such as gene recombination, microbial fermentation, and protein separation and purification, the company has achieved a unit expression level of 28 g/L and established an industrial-grade production system with an annual output capacity of 20 tons of recombinant collagen, ranking among the top globally in both expression levels and production scale.
Since the launch of the first recombinant Type V collagen product in 2024, Jiangsu Jland Biotech Co., Ltd. has successfully established a multi-type product portfolio covering Type I, Type III, Type IV, Type V, Type VII, Type XVII collagen, as well as fibronectin and elastin. The company has achieved deep application across cosmetics, medical devices, and nutritional food sectors, emerging as one of the leading suppliers of recombinant collagen with the largest global production capacity and the most comprehensive type spectrum.
Jiangsu Jland Biotech Co., Ltd. has undertaken multiple national-level scientific research projects, led the drafting of industry standards for recombinant collagen, and holds more than 50 authorized invention patents in China and abroad. As an international enterprise that has obtained quality certifications from six countries—China, the United States, the United Kingdom, Germany, France, and South Korea—and received FDA recognition for its self-GRAS certification, the company’s products are now exported to over 40 countries and regions worldwide, setting a high-standard benchmark for Chinese original collagen in the global market.
Jiangsu Jland Biotech Co., Ltd. will primarily allocate the funds from this round of financing to the following three key areas:
I. Enhance Production Capacity and Automation Levels: Expand and Upgrade Biomanufacturing “Super Factories” to Build an Intelligent Protein Production Platform;
II. Strengthen R&D and Application Innovation of Raw Materials: Continuously expand the functional development of collagen in fields such as medical devices and tissue engineering;
3. Expanding Global Market and Brand Layout: Advancing international registration and compliance to deeply empower major brand owners in the global pharmaceutical, healthcare, and aesthetics sectors with high-quality recombinant collagen ingredients, thereby further expanding into global markets including North America, Europe, and Southeast Asia.
JlandBirthThingChairmanChang LiangMr.Indicates:This financing round represents strong market recognition of Jland Biotech’s technology platform and business model. We will continue to achieve breakthroughs in green biomanufacturing, product and technological innovation, structural optimization, and scenario expansion, enabling next-generation collagen to serve global consumers and industry clients in a more sustainable and high-performance manner. Through synthetic biology technologies, we aim to make China-originated recombinant collagen the premier choice in the global high-end market.
SDIC Investment Promotion Life Sciences TeamIndicates:SDIC Merchants believes that the bio-manufacturing industry is a key sector supported by national strategy. Recombinant functional proteins are important biomaterials produced through bio-manufacturing, and their research, development, and application hold significant strategic importance in multiple fields, including biopharmaceuticals and high-end medical devices. SDIC Merchants will support the company in enhancing its technological R&D and scalable production capabilities, helping it become a global leader in recombinant functional protein biomaterials.
Mr. Lu Rong, Chairman of Yuexiu Industrial FundIndicates:Recombinant collagen is one of the functional protein materials with diverse application scenarios, and has become a high-growth sector that combines consumer and serious medical attributes. As an industry benchmark enterprise, Jiangsu Jland Biotech Co., Ltd. possesses domestically leading recombinant protein fermentation and purification technologies, as well as industry-leading innovation platforms, product iteration capabilities, and industrialization experience. Guangzhou YUEXIU Industrial Investment Fund Management Co.,Ltd. highly recognizes Jland Biotech’s technology commercialization capabilities and team execution strength. It will continue to practice empowering investment, fully integrate upstream and downstream resources, and actively support Jland Biotech in further enhancing its market influence and expanding into the global market.
The investors in this round, SDIC Merchants and YUEXIU Industrial Fund, are both strategic investment institutions that have long focused on the biomanufacturing and pharmaceutical healthcare sectors. They have highly recognized Juyuan Biotech’s R&D capabilities, industrial value, and growth potential.
With the successful completion of its Series C financing, Jiangsu Jland Biotech Co., Ltd. will accelerate its growth trajectory, driven by the dual engines of “technological ingredients + bio-manufacturing,” and continue to lead the recombinant collagen industry toward higher quality and stricter standards.
Amid the global wave of green manufacturing and precision health, Juyuan Biotech will rise to its mission, aiming to “make Chinese functional proteins shine on the world stage” and inject a continuous stream of “bio-intelligent manufacturing power” into the global beauty and wellness industry.
Jiangsu Jland Biotech Co., Ltd. is a high-tech biomanufacturing enterprise dedicated to the industrial design and application of biomimetic recombinant proteins. Since its establishment in 2015, the company has set up three marketing centers, four major production bases, and five R&D centers worldwide. It has built a full-industry-chain platform covering gene design, strain construction, industrial process development, ton-scale capacity scale-up, downstream application R&D, and safety and efficacy testing of downstream products. Leveraging advanced biotechnologies such as gene recombination, microbial fermentation, and protein separation and purification, the company has achieved large-scale production of multiple functional proteins. As one of the world’s largest manufacturers of recombinant collagen, it boasts globally leading unit expression levels for recombinant collagen.
SDIC Investment Promotion is a leading private equity investment management institution in China, specializing in investments in the advanced manufacturing industry. It places great emphasis on technological innovation and the value of outstanding entrepreneurs and teams, with a focus on investing in sectors such as intelligent manufacturing, new energy vehicles, life sciences, and information and communications technology (ICT). The firm is committed to promoting the green, digital, and service-oriented development of the manufacturing sector. The team has cumulatively managed assets totaling nearly RMB 100 billion, with investors including financial institutions, the National Social Security Fund, as well as state-owned and private capital.
Established in 2011, Yuexiu Industrial Investment Fund has managed cumulative assets exceeding RMB 200 billion. In the biomedical sector, the company has implemented full-industry-chain investment strategies across key segments such as innovative drug R&D, medical devices, and healthcare services. Through years of market-oriented and professional development, it has formed a business portfolio encompassing fund-of-funds investments, equity investments, and mezzanine investments. Guided by its mission to “implement national strategies, serve the real economy, foster technological innovation, and enhance people’s well-being,” the company is committed to becoming a leading industrial investment platform in China.